FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										

0.5

hours per response:

	Check this box if no longer subject
٦.	to Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					0, 000	2011	0(11) 01	i tiic	IIIVCSIIII	CIII C	Ullipally Act t	11540						1	
1. Name and Address of Reporting Person*  Manning Paul B					2. Issuer Name <b>and</b> Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [ VRCA ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 07/24/2023									ficer (give ti low)			r (specify	
200 GARRETT STREET, SUITE S						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CHARLOTTESVILLE VA 22902														F	orm filed by o orm filed by l erson				
(City)	(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - Non	n-Derivat	ive S	ecui	ities	Ac	quired	l, Di	sposed of	f, or E	Benefic	ially O	wned				
Date				. Transaction ate Month/Day/Y	ear)   E	2A. Deemed Execution Date, if any (Month/Day/Year)		´	3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)	ed (A) or str. 3, 4 an	d Secu Bene Own Follo	wing	Forn (D) o	ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Repo Tran (Inst	orted saction(s) r. 3 and 4)				
Common	Stock		(	07/24/202	23				P		200,000	A	\$5.02	7,8	7,851,128 <sup>(2)</sup>		D <sup>(3)</sup>		
Common Stock														6,	000,000		I	By PBM 2022 Grantor Retained Annuity Trust	
Common Stock													1,	1,481,719		I	See footnote <sup>(4)</sup>		
Common Stock														2	256,634		I	See footnote <sup>(5)</sup>	
		Tak									osed of, convertib				ned				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			ion Date,		ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		e Exer tion D n/Day/		7. Title Amou Securi Under Deriva Securi (Instr.	nt of ities lying ıtive	8. Price Derivati Security (Instr. 5)	derivativ Securitie	re es ally ig d tion(s)	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)	
					Code V		(A)	(D)	Date Exercisable		Expiration Date		or Number of Shares						

## Explanation of Responses:

- 1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$4.75 to \$5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 2. Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust. This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting.
- 3. The shares are held by Mr. Manning jointly with his spouse.
- 4. The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
- 5. The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.

## Remarks:

/s/ Mark Ballantyne, Attorney-in-Fact

07/24/2023

\*\* Signature of Reporting Person

n Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.